The cost effectiveness of human papillomavirus vaccines: a systematic review.

06:00 EDT 15th March 2012 | BioPortfolio

Summary of "The cost effectiveness of human papillomavirus vaccines: a systematic review."

Introduction: Human papillomavirus (HPV) is one of the world's most common sexually transmitted infections, and has been associated with a number of cervical and non-cervical diseases, including cancer. HPV vaccines have been licensed for use in females for some time, but the quadrivalent vaccine has only recently become licensed for use in males. Many countries have adopted a vaccination programme for adolescent females based on results of cost-effectiveness analyses. However, given the new indications for use of the vaccine in males, decision makers require information on the cost effectiveness of vaccinating males in order to make policy decisions on whether or not to fund such programmes. Objective: Our objective was to conduct a qualitative systematic review to update a previously conducted review of HPV vaccine studies. Methods: Articles were obtained from an extensive literature search to determine the cost effectiveness of implementing an HPV vaccination programme with routine cervical cancer screening. A total of 29 studies were included in this review. Seventeen of the included articles looked only at cervical disease outcomes, and 12 studies also included non-cervical disease outcomes. Four studies explored the economic impact of vaccinating both boys and girls. One study focused on a population of men who have sex with men (MSM). Results: While different model structures, input parameters and baseline assumptions were used, the consistent message in studies that focused on female-only vaccination programmes was that routine vaccination of females is cost effective compared with cervical cancer screening alone. Discussion: Based on the currently available literature, it appears that the addition of boys to a vaccination programme generally exceeds traditional cost-effectiveness thresholds. The MSM population represents a potential additional target for routine HPV vaccination; however, more cost-effectiveness studies are required before making such a policy change.


Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.

Journal Details

This article was published in the following journal.

Name: Drugs
ISSN: 0012-6667
Pages: 715-43


DeepDyve research library

PubMed Articles [32925 Associated PubMed Articles listed on BioPortfolio]

Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.

Introduction of human papillomavirus (HPV) vaccination for adolescent girls is being considered in the Punjab state of India. However, evidence regarding cost-effectiveness is sought by policy makers ...

Clinical effectiveness, cost-effectiveness and acceptability of community-based management of chronic hepatitis C: a mixed methods systematic review protocol.

The current mixed methods review aims to develop an aggregated synthesis of quantitative, qualitative and economic systematic evidence on chronic hepatitis C virus (HCV) infection management intervent...

Economic evaluations of Haemophilus influenzae type b (Hib) vaccine: a systematic review.

World Health Organization (WHO) recommends the use of Haemophilus influenzae type b (Hib) conjugate vaccines but only China and Thailand have not used Hib vaccination in their national immunization pr...

Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis.

To review evidence on the efficacy of HPV vaccines in the prevention of non-cancer lesions (anogenital warts [AGW], recurrent laryngeal papillomatosis and oral papillomatosis).

Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men.

Men who have sex with men (MSM) have a high lifetime risk of anogenital warts and cancers related to infection with human papillomavirus (HPV). They also benefit less from herd protection than heteros...

Clinical Trials [6843 Associated Clinical Trials listed on BioPortfolio]

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and ho...

Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer

RATIONALE: Vaccines made from certain human papillomaviruses may be able to help the body to kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of human papillomavi...

Immune Memory After Papillomavirus Vaccination

Vaccines for human papillomavirus (HPV) have been available in the United States since 2006. Early studies have shown a high rate of effectiveness of these vaccines, however it is not kno...

Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer

RATIONALE: Vaccines made from human papillomavirus may make the body build an immune response to and kill cervical cancer cells. Combining vaccine therapy with surgery may be a more effect...

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

DNA vaccines, which are small pieces of DNA also known as plasmids, have several advantages over traditional vaccines such as live attenuated virus and recombinant protein-based vaccines. ...

Medical and Biotech [MESH] Definitions

Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.

Organizations representing designated geographic areas which have contracts under the PRO program to review the medical necessity, appropriateness, quality, and cost-effectiveness of care received by Medicare beneficiaries. Peer Review Improvement Act, PL 97-248, 1982.

Formal programs for assessing drug prescription against some standard. Drug utilization review may consider clinical appropriateness, cost effectiveness, and, in some cases, outcomes. Review is usually retrospective, but some analysis may be done before drugs are dispensed (as in computer systems which advise physicians when prescriptions are entered). Drug utilization review is mandated for Medicaid programs beginning in 1993.

A type of human papillomavirus especially associated with malignant tumors of the genital and RESPIRATORY MUCOSA.

A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.

Quick Search

DeepDyve research library

Relevant Topic

Cervical Cancer
Cervical cancer is a malignant neoplasm of the cervix uteri or cervical area. Symptoms include vaginal bleeding, but may not present until later stages of the cancer. Cervical cancer can be treated using surgery (including local excision) in early stages...

Searches Linking to this Article